Revolution Medicines to Participate in November 2026 Investor Conferences
Revolution Medicines Inc Ordinary Shares RVMD
News
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Revolution Medicines Gets FDA Breakthrough Designation for Cancer Treatment
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA
Revolution Medicines' Pancreatic-Cancer Drug Cleared for Expanded Access
Revolution Medicines Shares Slide Premarket After Merck Talks Cool
AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition
Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment
United States